Loading
Life sciences · Journal article
Breast Cancer Research · September 17, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
There is an ongoing need for first-line (1L) chemotherapies for metastatic HER2-negative breast cancer. This study evaluated the efficacy and safety profile of the dose-expansion part 6 of Study 114 in patients receiving E7389-LF as a 1L chemotherapy for metastatic/advanced HER2-negative breast cancer. Japanese patients (≥ 20 years of age) with confirmed HER2-negative breast cancer (HER2-0 or HER2-low) were enrolled; subgroup analyses included luminal-like and triple-negative breast cancer tumors. Eligible patients had ≥ 1 measurable lesion per Response Evaluation Criteria in Solid Tumor version 1.1 (RECIST v1.1) and had not received prior chemotherapy for advanced/metastatic disease. Objectives included safety, efficacy, and biomarker changes. Tumors were assessed by investigators per RECIST v1.1. Twenty-six patients received E7389-LF. Overall, 24 patients (92.3%) had discontinued treatment by the data cutoff date (October 18, 2023). Most common treatment-related adverse events (TRAEs) of any grade were alopecia (88.5%), neutropenia (88.5%; grade ≥ 3, 76.9%), and thrombocytopenia (84.6%; grade ≥ 3, 34.6%). Three patients discontinued due to TRAEs. No patient showed a complete response, and 8 (30.8%) had confirmed partial responses, for an objective response rate of 30.8%. Median progression-free survival (PFS) was 8.1 months overall (patients with luminal breast cancer [n = 22]: 8.1 months; triple-negative breast cancer [n = 4]: 9.8 months). Median overall survival was not reached at 22.7 months of follow-up. Median PFS on next-line therapy was 20.6 months. Changes in vasculature- and IFNγ-related biomarkers were observed in all patients who received E7389-LF. These results highlight the antitumor activity and manageable safety profile of E7389-LF, indicating the potential of E7389-LF as a 1L treatment for patients with HER2-negative breast cancer, warranting further study. NCT03207672. Registered 5 July 2017.